Pegvisomant for severe insulin resistance from rare fat or gene problems
Part of Hormones & metabolism clinical trials.
This Phase 2 study tests pegvisomant, a medicine that blocks growth hormone, to see if it can improve severe insulin resistance in people with a specific genetic cause or a rare fat distribution condition. If you fit the rare diagnosis, the study may help clarify whether growth-hormone blocking can improve blood sugar and related health markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either a known insulin receptor gene change (dominant negative or recessive) OR a diagnosis of partial lipodystrophy with less body fat in certain areas (at least the thigh/hip area).
- You’re between 18 and 70 years old.
- You’ve finished linear growth and puberty.
- You have not used niacin or other medicines that directly affect fat breakdown (lipolysis) within the last 8 weeks.
- Your diabetes or cholesterol medicines have not changed within the last 2 weeks.
- You can and will sign the informed consent form and understand what the study involves.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.
This trial tests a new drug called mibavademab for people with generalized lipodystrophy, a condition where the body can't store fat properly, leading to problems like diabetes and high triglycerides. It aims to see if the drug safely improves these metabolic issues.
This study is looking for women with a type of severe insulin resistance linked to genetics, especially those who have PCOS or a condition called lipodystrophy. The goal is to better understand the genes involved so doctors can offer more targeted treatments.
This Phase 2 study tests two medicines to see how they change body fat, insulin sensitivity, and bone health in adults with obesity. It may help people who have tried lifestyle changes to lose weight but have not been able to, though diabetes and several health conditions must be ruled out first.
This study tests how your body responds to insulin by using a special test called a pancreatic clamp. It may help researchers understand insulin resistance better and find new ways to treat it.
Hear when a new Partial Lipodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.